Lindsay W. Brubaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lindsay W. Brubaker has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
196 shared publications - Miriam D. Post
University of Colorado Anschutz Medical Campus 4 Department of Pathology Aurora, Colorado
189 shared publications - Nicole Marjon
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
175 shared publications - Elizabeth R. Woodruff
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
101 shared publications - Ritsuko Iwanaga
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
101 shared publications - Tomomi M. Yamamoto
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
101 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Alisertib treatment reduces H2AK119ub expression.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Alisertib treatment reduces H2AK119ub expression.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Gating strategy for immune profiling shControl and shCBX2 tumors treated with alisertib.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Gating strategy for immune profiling shControl and shCBX2 tumors treated with alisertib.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Modulation of CBX2 uniquely impacts alisertib IC50.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Modulation of CBX2 uniquely impacts alisertib IC50.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Chromobox 2 (CBX2), a subunit of polycomb repressor complex 1 (PRC1), is expressed in high-grade serous carcinoma (HGSC). CBX2-inhibitory peptide (CBX2i) has demonstrated efficacy in a syngeneic mouse model but has limitations. We sought to identify an alternative approach to CBX2 inhibition. A computational-based molecular docking screen was performed using the Selleckchem Bioactive Library to identify inhibitors of CBX2. A similarity screen of top hits against the bound conformation of CBX2i pharmacophore model was performed in parallel. A series of in vitro validation studies evaluated the effect of alisertib on proliferation, a CBX2 target gene, and stemness. CBX2-knockdown cell lines and a syngeneic murine model were utilized to evaluate alisertib response in the context of CBX2 loss. Cell target engagement assay was performed. PRC1 activity was measured by H2AK119ub levels. Immune profiling of treated tumors defined the immune microenvironment. The computational-based screen identified 10 candidate compounds. In vitro validation narrowed compounds of interest to raltitrexed, alisertib, GTX-007, LY315920, and PD0325901. Ultralow dilution assay demonstrated a dramatic decrease in spheroid formation with alisertib, an aurora A kinase (AURKA) inhibitor. Good structural overlap was observed between CBX2i and alisertib. Cell target engagement assay confirmed alisertib selectivity for both AURKA and CBX2. Loss of CBX2 attenuated alisertib efficacy in vitro and in vivo. Treatment with alisertib leads to a decrease in H2AK119ub and shift in the immune tumor microenvironment. Alisertib efficacy in HGSC is dependent on functional CBX2, and cell target engagement confirms selectivity for CBX2, supporting that alisertib activity involves CBX2 inhibition.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor
Chromobox 2 (CBX2), a subunit of polycomb repressor complex 1 (PRC1), is expressed in high-grade serous carcinoma (HGSC). CBX2-inhibitory peptide (CBX2i) has demonstrated efficacy in a syngeneic mouse model but has limitations. We sought to identify an alternative approach to CBX2 inhibition. A computational-based molecular docking screen was performed using the Selleckchem Bioactive Library to identify inhibitors of CBX2. A similarity screen of top hits against the bound conformation of CBX2i pharmacophore model was performed in parallel. A series of in vitro validation studies evaluated the effect of alisertib on proliferation, a CBX2 target gene, and stemness. CBX2-knockdown cell lines and a syngeneic murine model were utilized to evaluate alisertib response in the context of CBX2 loss. Cell target engagement assay was performed. PRC1 activity was measured by H2AK119ub levels. Immune profiling of treated tumors defined the immune microenvironment. The computational-based screen identified 10 candidate compounds. In vitro validation narrowed compounds of interest to raltitrexed, alisertib, GTX-007, LY315920, and PD0325901. Ultralow dilution assay demonstrated a dramatic decrease in spheroid formation with alisertib, an aurora A kinase (AURKA) inhibitor. Good structural overlap was observed between CBX2i and alisertib. Cell target engagement assay confirmed alisertib selectivity for both AURKA and CBX2. Loss of CBX2 attenuated alisertib efficacy in vitro and in vivo. Treatment with alisertib leads to a decrease in H2AK119ub and shift in the immune tumor microenvironment. Alisertib efficacy in HGSC is dependent on functional CBX2, and cell target engagement confirms selectivity for CBX2, supporting that alisertib activity involves CBX2 inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S10. Example antibody staining images. Raw antibody staining images are shown here for an example FOV (FOV ID 9).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S10. Example antibody staining images. Raw antibody staining images are shown here for an example FOV (FOV ID 9).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S14. Ranking of feature importance in the random forest model for only primary tumor samples. Ranking of median Gini importance values for all features across 500 evaluations predicting OS and PFS, with the model trained only on primary tumor samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S14. Ranking of feature importance in the random forest model for only primary tumor samples. Ranking of median Gini importance values for all features across 500 evaluations predicting OS and PFS, with the model trained only on primary tumor samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S22 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S22. Random forest feature importance results split by feature type - PFS. Feature importance results for progression-free survival show in Figure 7B, split by feature type and split by subtype for spatial network features.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S22 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S22. Random forest feature importance results split by feature type - PFS. Feature importance results for progression-free survival show in Figure 7B, split by feature type and split by subtype for spatial network features.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S10. Correlation coefficients between other cell type percentages and tumor cell percentages. Full list of Pearson correlation coefficients between tumor cell percentage and cell type percentage, two-sided p-values and false discovery rate adjusted p-values are reported, with significance determined by the latter.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Table S10. Correlation coefficients between other cell type percentages and tumor cell percentages. Full list of Pearson correlation coefficients between tumor cell percentage and cell type percentage, two-sided p-values and false discovery rate adjusted p-values are reported, with significance determined by the latter.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S14. Median neighbor distances in the spatial networks. Heatmap of the median distances (μm) between spatial network neighbors of pairs of cell types aggregated across all edges included in the final set of samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma
Fig S14. Median neighbor distances in the spatial networks. Heatmap of the median distances (μm) between spatial network neighbors of pairs of cell types aggregated across all edges included in the final set of samples.